Published in Ochsner J on January 01, 2002
Recent publications by ochsner authors. Ochsner J (2003) 0.75
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med (1997) 19.14
Human blood pressure determination by sphygmomanometry. Circulation (1993) 7.88
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) Arch Intern Med (1993) 5.08
Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med (1998) 5.00
Diabetes, hypertension, and cardiovascular disease: an update. Hypertension (2001) 4.62
The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med (1988) 3.75
The heart in hypertension. N Engl J Med (1992) 2.53
Review of the overall experience of captopril in hypertension. Arch Intern Med (1984) 1.99
Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res (1981) 1.75
One-year longitudinal study of a no-smoking policy in a medical institution. Chest (1990) 1.75
Hyperdynamic beta-adrenergic circulatory state. Arch Intern Med (1966) 1.57
Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med (1981) 1.48
Reference sample microsphere method: cardiac output and blood flows in conscious rat. Am J Physiol (1980) 1.37
Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med (1984) 1.31
Tilt test for investigating a neural component in hypertension. Its correlation with clinical characteristics. Circulation (1967) 1.17
Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med (1983) 1.16
Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation (1982) 1.16
Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol (1979) 1.14
Hyperdynamic beta-adrenergic circulatory state. Increased beta-receptor responsiveness. Arch Intern Med (1969) 1.14
State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension (1999) 1.13
The first Irvine H. Page lecture. The mosaic of hypertension: past, present and future. J Hypertens Suppl (1988) 1.13
Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol (1979) 1.13
Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension (1981) 1.13
Regional blood flows measured in conscious rats by combined Fick and microsphere methods. Am J Physiol (1978) 1.10
Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res (1976) 1.06
Clinical-physiological correlations in the development of hypertensive heart disease. Circulation (1971) 1.06
Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol (1977) 1.06
Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol (1993) 1.05
ACC revised recommendations for training in adult cardiovascular medicine. Core Cardiology Training II (COCATS 2). (Revision of the 1995 COCATS training statement). J Am Coll Cardiol (2002) 1.03
Plasma volume in men with essential hypertension. N Engl J Med (1968) 1.02
Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation (1984) 1.01
Pathophysiologic significance of "stress" or relative polycythemia in essential hypertension. Am J Cardiol (1976) 1.00
Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-L>-arginine methyl ester/spontaneously hypertensive rats. Hypertension (2001) 1.00
Recent advances on large arteries in hypertension. Hypertension (1998) 1.00
Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension (1996) 0.99
Greater renal vascular involvement in the black patient with essential hypertension. A comparison of systemic and renal hemodynamics in black and white patients. Miner Electrolyte Metab (1984) 0.99
Physiological comparison of labile and essential hypertension. Circ Res (1970) 0.99
Racial differences in cardiac adaptation to essential hypertension determined by echocardiographic indexes. J Am Coll Cardiol (1983) 0.97
Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol (1984) 0.97
Re-examination of the hemodynamics of hypertension. Am J Med Sci (1969) 0.96
Heart, aging, and hypertension. Curr Opin Cardiol (2001) 0.95
Total vascular pressure-volume relationship in the conscious rat. Am J Physiol (1980) 0.95
Limited echocardiography for hypertensive left ventricular hypertrophy. Hypertension (1997) 0.95
Electrocardiographic changes reflecting left atrial abnormality in hypertension. Circulation (1966) 0.94
Renal haemodynamic studies in obesity hypertension. J Hypertens (1987) 0.94
Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol (1985) 0.93
Borderline hypertension: relationship between age, hemodynamics and circulating catecholamines. Circulation (1981) 0.93
Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension. Am J Cardiol (1983) 0.93
Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension (1997) 0.91
Stress and hypertension. J Hypertens Suppl (1990) 0.91
A hemodynamic comparison of essential and renovascular hypertension. Cardiac output and total peripheral resistance: supine and tilted patients. Circulation (1967) 0.90
Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med (1983) 0.90
Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens (2001) 0.90
Hemodynamic differences between black patients and white patients with essential hypertension. State of the art lecture. Hypertension (1990) 0.90
Increased ANF secretion after volume expansion is preserved in rats with heart failure. Am J Physiol (1988) 0.89
Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens (1999) 0.89
Fluid volumes during onset of spontaneous hypertension in rats. Am J Physiol (1978) 0.88
Atrial natriuretic peptide increases resistance to venous return in rats. Am J Physiol (1987) 0.86
Hemodynamic and myocardial function in young and old normotensive and spontaneously hypertensive rats. Circ Res (1973) 0.86
Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension (1999) 0.85
Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens (1998) 0.85
Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. J Hypertens (1997) 0.84
Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens (2002) 0.84
Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy? Circulation (1987) 0.84
Action of Nitroglycerin and amyl nitrite in labile and essential hypertension: hemodynamic differences. Arch Intern Med (1977) 0.83
The cardiovascular responses to exercise in children across the blood pressure distribution. The Muscatine study. Hypertension (1983) 0.82
Effect of methyldopa, clonidine, and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats. Cardiovasc Res (1982) 0.82
Isolated systolic hypertension in elderly WKY is reversed with L-arginine and ACE inhibition. Hypertension (2001) 0.82
Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors. Hypertension (2001) 0.82
Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension (1999) 0.82
Hemodynamic, reflexive, and metabolic alterations induced by acute and chronic timolol therapy in hypertensive man. Circulation (1978) 0.82
Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension (1998) 0.82
Systemic hemodynamic effects of microspheres in conscious rats. Am J Physiol (1977) 0.82
Atrial natriuretic peptide decreases circulatory capacitance in areflexic rats. Circ Res (1986) 0.81
Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. Hypertension (1995) 0.81
Hemodynamic factors in the pathogenesis and maintenance of hypertension. Fed Proc (1982) 0.81
Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension (1997) 0.81
Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension (2001) 0.81
Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens (1996) 0.81
Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation (1987) 0.81
Decreased total venous capacity in Goldblatt hypertensive rats. Am J Physiol (1981) 0.80
Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation (1986) 0.79
Renal artery stenosis and polycystic kidney disease. Arch Intern Med (1978) 0.79
Overview of hemodynamic and non-hemodynamic factors associated with left ventricular hypertrophy. J Mol Cell Cardiol (1989) 0.79
Left ventricular hypertrophy, cardiac diseases and hypertension: recent experiences. J Am Coll Cardiol (1989) 0.79
Local hemodynamic changes in hypertension: insights for therapeutic preservation of target organs. Hypertension (2001) 0.79
Angiotensin converting enzyme inhibitors. Present and future. Hypertension (1989) 0.79
Development of SHR hypertension and cardiac hypertrophy during prolonged beta blockade. Am J Physiol (1977) 0.79
Hemodynamics and other determinants in development of left ventricular hypertrophy. Fed Proc (1983) 0.78
Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med (1986) 0.78
Ventricular morphology and pumping ability of exercised spontaneously hypertensive rats. Am J Physiol (1978) 0.78
Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension (1991) 0.78
Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens (1996) 0.78
The heart in hypertension: a 1991 overview. Hypertension (1991) 0.77
ECG alterations with progressive left ventricular hypertrophy in spontaneous hypertension. Clin Exp Hypertens (1978) 0.77
Whole-body venous capacity and effective total tissue compliance in SHR. Hypertension (1981) 0.77
The problem of obesity and hypertension. Hypertension (1983) 0.77
Clinical and hemodynamic determinants of left ventricular dimensions. Arch Intern Med (1984) 0.77
Immediate regional blood flow distribution following angiotensin converting enzyme inhibition in patients with essential hypertension. Am J Med (1984) 0.77
Annual ochsner graduate medical education house staff graduation speakers. Ochsner J (2002) 0.76